Clinical Trials or Protocols are scientific studies that allow physicians to find new and better methods of treating cancer patients. The Clinical Trials test many new drugs, approaches to different therapies, and surgeries in order to gain more knowledge about side effects and what treatments work best. This places our physicians in a position to offer our patients the most up-to-date treatments available.
Hematology and Oncology Associates is a member of the Jefferson Cancer Network and has been recognized by them for outstanding accrual to clinical trials. This affiliation with Jefferson Cancer Center allows our physicians to have access to the most up to date clinical trials without requiring our patients to travel for this treatment. Our physicians are research oriented and remain dedicated to investigating new treatment modalities for care of the cancer patient. They attend various conferences throughout the year to stay current with new drugs, procedures, and therapies in an effort to continuously provide up-to-date services and care to our patients. By doing so, our physicians are able to offer the benefit of local care to those who might otherwise have to travel great distances from their home community in order to take advantage of the newest treatment options available. Staff in the Research Department, including an oncology certified Registered Nurse, are all dedicated to aiding the physicians in the treatment and patient care issues of our Clinical Trial participants.
National Cancer Institute
Open Clinical Trials
- AML Registry Trial: Newly diagnosed AML patients complete quarterly QOL questionnaires
- SWOG 1207: Randomized, placebo controlled trial of adjuvant endocrine therapy +/- Everolimus for 1 year in hormone +, HER 2 negative Breast Cancer Patients
- NRG-BR003: Randomized trial of adjuvant chemotherapy with or without Carboplatin for node positive or high risk node negative triple negative breast cancer.
- AFT-05 (PALLAS): Randomized trial of Palbociclib with endocrine therapy vs endocrine therapy alone for hormone receptor+ , HER 2- early breast cancer
- ONT-380-206: Randomized, double blind study of ONT 380 / Placebo in combination with Xeloda + Herceptin in previously treated HER 2+ breast cancer.
- Dompe REP 0114:Randomized, double blind trial of Taxol with or without Reparixin for metastatic triple negative breast cancer.
- CLL:Registry trial for CLL patients
- No active clinical trials
- NCIC BR-31: Double blind, randomized trial of adjuvant MEDI4736 in completely resected NSCLC
- Celgene NHL-008: Randomized trial of Lenalidomide plus Rituxan maintenance therapy followed by Lenolidimide single agent maintenance vs Rituxan maintenance in patients with relapsed/refractory marginal zone of mantle cell NHL.
- MDS Registry Trial: Newly diagnosed AML patients complete quarterly QOL questionnaires
- Incyte INCB 401:: Observational trial for patients with low risk Myelofibrosis or high risk Essential Thrombocythemia